Oncology – Page 30

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance

By MedXY 08/07/2025

Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profiles.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications

By MedXY 08/07/2025

Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.

Clinical Updates news Oncology Radiology Specialties

Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial

By MedXY 08/07/2025

The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurrence risk.

Clinical Updates news Oncology Specialties

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

By MedXY 08/07/2025

A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.

Clinical Updates General Surgery news Oncology Specialties

Long-Term Outcomes of Transoral Surgery with Risk-Adapted Adjuvant Therapy in HPV-Positive Oropharyngeal Cancer: Results from the E3311 Trial

By MedXY 08/07/2025

The E3311 phase II trial shows excellent long-term survival with deintensified postoperative management after transoral surgery in HPV-associated oropharyngeal cancer, with most patients spared from high-dose radiation and chemotherapy.

Clinical Updates news Oncology Specialties

Personalizing Oxaliplatin Dosing: Reducing Neurotoxicity in Stage III Colon Cancer—Insights from the LEANOX Trial

By MedXY 08/07/2025

LBM-based oxaliplatin dosing significantly reduces peripheral neurotoxicity without compromising survival outcomes in adjuvant treatment for stage III colon cancer.

Clinical Updates General Surgery news Oncology Specialties

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Clinical Updates Oncology Specialties Urology

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine

By Dr.Paul 08/07/2025

Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…

Clinical Updates Oncology Specialties

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

By MedXY 08/07/2025

The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.

Clinical Updates news Oncology Specialties

Revolutionizing Cancer Therapy: Synergistic Action of Two Natural Bacteria in Complete Tumor Eradication

By MedXY 08/06/2025

A novel bacteria-based therapy using two natural strains demonstrates complete tumor clearance in immunocompromised models, offering hope for cancer patients unsuitable for current immunotherapies.

Clinical Updates news Oncology Specialties

Curcumin Shows Promise in Targeting Colorectal Cancer Stem-like Cells: Mechanistic Insights and Clinical Implications

By MedXY 08/06/2025

Curcumin, derived from turmeric, targets colorectal cancer stem-like cells, inhibits tumor growth, and promotes differentiation, offering new opportunities for cancer prevention strategies.

Clinical Updates Family Medicine & Nutrition news Oncology Specialties

Vitamin C as a Cardioprotective Agent Against Doxorubicin-Induced Cardiotoxicity

By MedXY 08/06/2025

This review explores vitamin C's potential to protect the heart from doxorubicin-induced damage by reducing oxidative stress and preserving cardiac function, highlighting the need for further clinical studies.

Clinical Updates news Oncology Specialties

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

By MedXY 08/06/2025

This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.

Clinical Updates news Oncology Specialties

Beyond Negative: Quantitative Fecal Hemoglobin Levels Refine Colorectal Cancer Risk Stratification in FIT-based Screening

By MedXY 08/06/2025

New meta-analysis reveals a strong dose-response relationship between fecal hemoglobin concentration and colorectal neoplasia risk, even among FIT-negative individuals, supporting personalized screening intervals.

Clinical Updates news Oncology Specialties

Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting

By MedXY 08/06/2025

PD-1 inhibitor resistance is a major hurdle in cancer immunotherapy. Six leading combination strategies—including chemotherapy, anti-angiogenic agents, radiotherapy, novel checkpoint inhibitors, microbiome modulation, and ADCs—offer new hope for overcoming resistance and improving patient outcomes.

Medical News news Oncology Specialties

Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk

By MedXY 08/05/2025

A large pooled analysis across continents confirms a linear, dose-dependent association between alcohol consumption and pancreatic cancer risk—independent of smoking status and with significant public health implications.

Clinical Updates news Oncology Specialties

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

By MedXY 08/05/2025

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.

$A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children$

Clinical Updates news Oncology Specialties

A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children

By MedXY 08/05/2025

A phase I trial published in JCO demonstrates that a novel combination of MIBG, dinutuximab, and vorinostat achieves up to 75% disease control in relapsed/refractory neuroblastoma, offering new hope for high-risk pediatric patients.

Clinical Updates news Oncology Specialties

Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations

By MedXY 08/05/2025

A comprehensive meta-analysis confirms that Helicobacter pylori eradication reduces gastric cancer risk and related deaths, especially benefiting high-risk groups, supporting widespread screening and treatment.